Securities code: 688658 securities abbreviation: Youcare Pharmaceutical Group Co.Ltd(688658) Announcement No.: 2022-004 Youcare Pharmaceutical Group Co.Ltd(688658)
Announcement of resolutions of the 19th meeting of the first board of directors
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
1、 Convening of board meeting
The 19th meeting of the first board of directors (hereinafter referred to as “the meeting”) of Youcare Pharmaceutical Group Co.Ltd(688658) (hereinafter referred to as “the company”) was held on January 7, 2022 by means of on-site and video communication. The meeting was convened and presided over by Mr. Yu Weishi, chairman of the board of directors. The convening and convening procedures of this meeting comply with the provisions of relevant laws, administrative regulations, departmental rules, normative documents and the articles of association, and the resolutions of the meeting are legal and effective.
2、 Deliberations of the board meeting
(I) deliberated and passed the proposal on signing technology transfer contract with Institute of pathogenic biology, Chinese Academy of Medical Sciences
The board of Directors believes that this cooperation is based on the development needs of the company’s innovation and upgrading strategy, focuses on the advantageous fields of the company’s antiviral indications, takes advantage of the company’s own technology and platform advantages in drug R & D and production, and participates in the development of broad-spectrum coronavirus membrane fusion inhibitor peptide drugs, which is a further supplement and improvement to the company’s existing R & D pipeline, Enhanced the company’s core competitiveness in the field of innovative drugs and consolidated the company’s innovative drug development strategy.
For details, see the company’s disclosure on the website of Shanghai Stock Exchange (www.sse. Com. CN.) on January 10, 2022 Announcement on voluntary disclosure of peptide drugs for broad-spectrum coronavirus membrane fusion inhibitors developed in cooperation with Institute of pathogenic biology, Chinese Academy of Medical Sciences (Announcement No.: 2022-003).
Voting results: 9 in favor, 0 against and 0 abstention.
(II) deliberated and passed the proposal on granting restricted shares to incentive objects for the first time
In accordance with the relevant provisions of the measures for the administration of equity incentive of listed companies, the Youcare Pharmaceutical Group Co.Ltd(688658) 2021 restricted stock incentive plan (Draft) and the authorization of the company’s fourth extraordinary general meeting in 2021, the board of Directors considers that the granting conditions specified in the company’s 2021 restricted stock incentive plan have been met, and agrees to take January 7, 2022 as the first granting date, 10.519 million restricted shares were granted to 113 incentive objects at the grant price of 10.97 yuan / share.
The independent directors of the company expressed their independent opinions.
Voting results: 4 in favor, 0 against and 0 abstention.
Avoidance of voting: affiliated directors Yu Weishi, Yu Fei, Zhang Jiang, Zhang Qibo and Yu Pengfei avoided voting on this proposal.
The contents of this proposal are detailed in the company’s disclosure on the website of Shanghai Stock Exchange (www.sse. Com. CN.) on January 10, 2022 Announcement of Youcare Pharmaceutical Group Co.Ltd(688658) on granting restricted shares to incentive objects for the first time (Announcement No.: 2022-006).
It is hereby announced.
Youcare Pharmaceutical Group Co.Ltd(688658) board of directors January 10, 2022
